Skip to main content
ACLX logo

ACLX · Arcellx, Inc.

Track ACLX — free
Market Cap
$6.73B
Shares
58.48M

No Price Data

No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.

Up next

Next earnings call
Oct 31, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Feb 26, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Limited Momentum Limited Sentiment Neutral Fundamentals Weak Quant / Vol Limited
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Limited
Not enough data for a confident read.
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-99% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.08% of float · ▼ -20.7% MoM · 2.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Fundamentals
Weak
Revenue growth −79%
Y/Y
EPS growth −104%
Y/Y
Free cash flow $-212.6M
Balance sheet $80.3M
net cash
Quant / Vol
risk profile
Limited
Not enough data for a confident read.

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACLX
Arcellx, Inc.
this stock
$6.73B -79.4% 3.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
$64.66B +23.6% 2.1%
CSLLY
Csl Ltd
$57.97B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
0.1%
Net QoQ
-58.4M sh
Top holder
DekaBank Deutsche Girozen…
Held Float
View
Held by Funds
Fund positions
94
View
Short & Settlement
Short Interest Falling
Shares short
1.8M
Days to cover
2.5d
Change
-469.5K sh
View
Short Volume
Short vol %
49%
As of
Apr 27, 2026
Short Total
View
Fails to Deliver
FTD shares
13.3K
Value
$1.5M
As of
Apr 29, 2026
View
Financials
Financials
Revenue (FY)
$22.3M
Net income (FY)
$-228.9M
EPS diluted
$-4.07
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Jun 9, 2026
This year
9
View
Proposed Sales
Value
$10.2M
Shares
89.9K
Filed
Feb 27, 2026
View
Exempt Offerings
Offering
$100.0M
Filed
Feb 6, 2023
View
Earnings & Events
Earnings Calls
Last call
Aug 4, 2026
View
Investor Relations
Latest news
CORRECTING and REPLACING Gilead S…
Published
Aug 5, 2026
View
Key facts CIK 1786205 CUSIP 03940C100 13F (30d) 8 filings 5 filers Visit website Investor relations